Protection against β-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice
Ji-Jing Yana, 1, Do-Hoon Kimb, 1, Yoo-Sun Moonc, Jun-Sub Junga, Eun-Mi Ahnd, Nam-In Baekd and Dong-Keun SongCorresponding Author Contact Information, a, Corresponding Author Contact Information, E-mail The Corresponding Author
a Department of Pharmacology, College of Medicine, Institute of Natural Medicine, Hallym University, Chunchon, Kangwon-Do, 200-702, South Korea
b Department of Psychiatry, College of Medicine, Institute of Natural Medicine, Hallym University, Chunchon, Kangwon-Do, 200-702, South Korea
c Department of Family Medicine, College of Medicine, Institute of Natural Medicine, Hallym University, Chunchon, Kangwon-Do, 200-702, South Korea
d Graduate School of Biotechnology and Plant Metabolism Research Center, Kyung Hee University, Yongin, Kyunggi-Do, 449-701, South Korea
Accepted 11 July 2003.
Available online 2 September 2003. Abstract
We investigated the effect of long-term oral administration of ethanolic extract of Angelica gigas Nakai (Umbelliferae) (EAG) or decursinol, a coumarin isolated from A. gigas, on β-amyloid peptide 142 (Aβ142)-induced memory impairment in mice. Mice were allowed free access to drinking water (control) or water containing different concentrations of EAG. After 4 weeks, Aβ142 (410 pmol) was administered via intracerebroventricular injection. Pretreatment of mice with EAG (0.1%) for 4 weeks significantly blocked the Aβ142-induced impairment in passive avoidance performance. Next, mice were fed with chow mixed with various doses of decursinol for 4 weeks before intracerebroventricular injection of Aβ142 (410 pmol). Pretreatment of mice with decursinol (0.001%, 0.002%, and 0.004%) for 4 weeks significantly attenuated the Aβ142-induced impairment in passive avoidance performance. Decursinol (0.004%) also significantly blunted the Aβ142-induced decrease in alternation behavior (spatial working memory) in the Y-maze test without change in general locomotor activity. These findings suggest that EAG or decursinol may have preventive effect against memory impairment related with Aβ of Alzheimer's disease.